Scicali R, Di Pino A, Platania R, Purrazzo G, Ferrara V, Giannone A, Urbano F, Filippello A, Rapisarda V, Farruggia E, Piro S, Rabuazzo A M, Purrello F
Department of Clinical and Experimental Medicine, University of Catania, Italy.
Department of Clinical and Experimental Medicine, Section of Occupational Medicine, University of Catania, Italy.
Nutr Metab Cardiovasc Dis. 2018 Jan;28(1):35-43. doi: 10.1016/j.numecd.2017.07.003. Epub 2017 Jul 18.
Familial hypercholesterolemia (FH) is underdiagnosed and public cholesterol screening may be useful to find new subjects. In this study, we aim to investigate the prevalence of FH patients in a hospital screening program and evaluate their atherosclerotic burden using intima-media thickness (IMT).
We screened 1575 lipid profiles and included for genetic analysis adults with a low-density lipoprotein (LDL) cholesterol >190 mg/dL and triglycerides <200 mg/dL and first-degree child relatives with LDL cholesterol >160 mg/dL and triglycerides <200 mg/dL. The diagnosis of FH was presumed by Dutch Lipid Clinic Network (DLCN) criteria and confirmed by the presence of the genetic variant. Mean common carotid intima-media thickness (IMT) was assessed using consensus criteria. After confirming LDL cholesterol value and excluding secondary hypercholesterolemia, 56 subjects with a DLCN ≥4 performed genetic analysis. Of these, 26 had an FH genetic variant. The proportion of patients with a mutation having a DLCN score of 6-8 was 75%; in individuals with a DLCN score >8 it was 100%. Mean IMT was higher in FH patients compared to non FH (0.73 [0.61-0.83] vs 0.71 [0.60-0.75] mm, p < 0.01). Moreover, we detected two mutations not previously described. Finally, simple regression analysis showed a correlation of IMT with LDL cholesterol >190 mg/dL and corneal arcus (p < 0.01 and p < 0.001, respectively).
A hospital screening was useful to detect FH subjects with increased atherosclerosis. Also, next-generation sequencing was able to detect new FH mutations.
家族性高胆固醇血症(FH)的诊断率较低,而公共胆固醇筛查可能有助于发现新病例。在本研究中,我们旨在调查医院筛查项目中FH患者的患病率,并使用内膜中层厚度(IMT)评估他们的动脉粥样硬化负担。
我们筛查了1575份血脂谱,纳入进行基因分析的对象为低密度脂蛋白(LDL)胆固醇>190mg/dL且甘油三酯<200mg/dL的成年人,以及LDL胆固醇>160mg/dL且甘油三酯<200mg/dL的一级儿童亲属。FH的诊断依据荷兰脂质诊所网络(DLCN)标准推定,并通过基因变异的存在得以证实。使用共识标准评估平均颈总动脉内膜中层厚度(IMT)。在确认LDL胆固醇值并排除继发性高胆固醇血症后,56名DLCN≥4的受试者进行了基因分析。其中,26人有FH基因变异。DLCN评分为6 - 8的突变患者比例为75%;DLCN评分>8的个体中这一比例为100%。FH患者的平均IMT高于非FH患者(0.73[0.61 - 0.83] vs 0.71[0.60 - 0.75]mm,p<0.01)。此外,我们检测到两个先前未描述的突变。最后,简单回归分析显示IMT与LDL胆固醇>190mg/dL和角膜弓相关(分别为p<0.01和p<0.001)。
医院筛查有助于检测出动脉粥样硬化增加的FH患者。此外,新一代测序能够检测到新的FH突变。